¹ 2 WELLBUTRIN SR[®]

3 (bupropion hydrochloride)

4 Sustained-Release Tablets

5 6


Suicidality in Children and Adolescents

7 Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in 8 short-term studies in children and adolescents with Major Depressive Disorder (MDD) and 9 other psychiatric disorders. Anyone considering the use of WELLBUTRIN SR or any other 10 antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, 11 12 suicidality, or unusual changes in behavior. Families and caregivers should be advised of 13 the need for close observation and communication with the prescriber. WELLBUTRIN SR 14 is not approved for use in pediatric patients. (See WARNINGS and PRECAUTIONS: 15 **Pediatric Use.**) 16 Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 17 9 antidepressant drugs (SSRIs and others) in children and adolescents with major 18 depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric 19 disorders (a total of 24 trials involving over 4,400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few 20 21 months of treatment in those receiving antidepressants. The average risk of such events in

- 22 patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides
- 23 occurred in these trials.

24 **DESCRIPTION**

- 25 WELLBUTRIN SR (bupropion hydrochloride), an antidepressant of the aminoketone class, is
- 26 chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other
- 27 known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related
- to phenylethylamines. It is designated as (\pm) -1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-
- 29 propanone hydrochloride. The molecular weight is 276.2. The molecular formula is
- 30 $C_{13}H_{18}CINO \cdot HCl$. Bupropion hydrochloride powder is white, crystalline, and highly soluble in
- 31 water. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa. The
- 32 structural formula is:



33 34

- 35 WELLBUTRIN SR Tablets are supplied for oral administration as 100-mg (blue), 150-mg
- 36 (purple), and 200-mg (light pink), film-coated, sustained-release tablets. Each tablet contains the
- 37 labeled amount of bupropion hydrochloride and the inactive ingredients: carnauba wax, cysteine
- 38 hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene
- 39 glycol, polysorbate 80, and titanium dioxide and is printed with edible black ink. In addition, the
- 40 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C Blue No. 2
- 41 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 Lake.

42 CLINICAL PHARMACOLOGY

- 43 **Pharmacodynamics:** Bupropion is a relatively weak inhibitor of the neuronal uptake of
- 44 norepinephrine, serotonin, and dopamine, and does not inhibit monoamine oxidase. While the
- 45 mechanism of action of bupropion, as with other antidepressants, is unknown, it is presumed that
- 46 this action is mediated by noradrenergic and/or dopaminergic mechanisms.
- 47 **Pharmacokinetics:** Bupropion is a racemic mixture. The pharmacologic activity and
- 48 pharmacokinetics of the individual enantiomers have not been studied. The mean elimination
- 49 half-life (\pm SD) of bupropion after chronic dosing is 21 (\pm 9) hours, and steady-state plasma
- 50 concentrations of bupropion are reached within 8 days. In a study comparing chronic dosing with
- 51 WELLBUTRIN SR Tablets 150 mg twice daily to the immediate-release formulation of
- 52 bupropion at 100 mg 3 times daily, peak plasma concentrations of bupropion at steady state for
- 53 WELLBUTRIN SR Tablets were approximately 85% of those achieved with the
- 54 immediate-release formulation. There was equivalence for bupropion AUCs, as well as
- equivalence for both peak plasma concentration and AUCs for all 3 of the detectable bupropion
- 56 metabolites. Thus, at steady state, WELLBUTRIN SR Tablets, given twice daily, and the
- 57 immediate-release formulation of bupropion, given 3 times daily, are essentially bioequivalent
- 58 for both bupropion and the 3 quantitatively important metabolites.
- 59 **Absorption:** Following oral administration of WELLBUTRIN SR Tablets to healthy
- 60 volunteers, peak plasma concentrations of bupropion are achieved within 3 hours. Food
- 61 increased C_{max} and AUC of bupropion by 11% and 17%, respectively, indicating that there is no
- 62 clinically significant food effect.
- 63 **Distribution:** In vitro tests show that bupropion is 84% bound to human plasma proteins at
- 64 concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion
- 65 metabolite is similar to that for bupropion, whereas the extent of protein binding of the
- 66 threohydrobupropion metabolite is about half that seen with bupropion.
- 67 *Metabolism:* Bupropion is extensively metabolized in humans. Three metabolites have been 68 shown to be active: hydroxybupropion, which is formed via hydroxylation of the *tert*-butyl group
- 69 of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion,
- 70 which are formed via reduction of the carbonyl group. In vitro findings suggest that cytochrome
- 71 P450IIB6 (CYP2B6) is the principal isoenzyme involved in the formation of hydroxybupropion,
- while cytochrome P450 isoenzymes are not involved in the formation of threohydrobupropion.
- 73 Oxidation of the bupropion side chain results in the formation of a glycine conjugate of

74 meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite. The potency

and toxicity of the metabolites relative to bupropion have not been fully characterized. However,

it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is

one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-

78 fold less potent than bupropion. This may be of clinical importance because the plasma

concentrations of the metabolites are as high or higher than those of bupropion.

80 Because bupropion is extensively metabolized, there is the potential for drug-drug

81 interactions, particularly with those agents that are metabolized by the cytochrome P450IIB6

82 (CYP2B6) isoenzyme. Although bupropion is not metabolized by cytochrome P450IID6

83 (CYP2D6), there is the potential for drug-drug interactions when bupropion is co-administered

84 with drugs metabolized by this isoenzyme (see PRECAUTIONS: Drug Interactions).

85 Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur

86 approximately 6 hours after administration of WELLBUTRIN SR Tablets. Peak plasma

87 concentrations of hydroxybupropion are approximately 10 times the peak level of the parent drug

at steady state. The elimination half-life of hydroxybupropion is approximately $20 (\pm 5)$ hours,

and its AUC at steady state is about 17 times that of bupropion. The times to peak concentrations

90 for the erythrohydrobupropion and threohydrobupropion metabolites are similar to that of the

91 hydroxybupropion metabolite. However, their elimination half-lives are longer, $33 (\pm 10)$ and 37

92 (± 13) hours, respectively, and steady-state AUCs are 1.5 and 7 times that of bupropion,

93 respectively.

Bupropion and its metabolites exhibit linear kinetics following chronic administration of 300
to 450 mg/day.

96 *Elimination:* Following oral administration of 200 mg of ¹⁴C-bupropion in humans, 87% and

97 10% of the radioactive dose were recovered in the urine and feces, respectively. However, the

98 fraction of the oral dose of bupropion excreted unchanged was only 0.5%, a finding consistent

99 with the extensive metabolism of bupropion.

100 **Population Subgroups:** Factors or conditions altering metabolic capacity (e.g., liver disease,

101 congestive heart failure [CHF], age, concomitant medications, etc.) or elimination may be

102 expected to influence the degree and extent of accumulation of the active metabolites of

103 bupropion. The elimination of the major metabolites of bupropion may be affected by reduced

104 renal or hepatic function because they are moderately polar compounds and are likely to undergo

105 further metabolism or conjugation in the liver prior to urinary excretion.

Hepatic: The effect of hepatic impairment on the pharmacokinetics of bupropion was
 characterized in 2 single-dose studies, one in patients with alcoholic liver disease and one in

- 108 patients with mild to severe cirrhosis. The first study showed that the half-life of
- 109 hydroxybupropion was significantly longer in 8 patients with alcoholic liver disease than in
- 110 8 healthy volunteers (32±14 hours versus 21±5 hours, respectively). Although not statistically

significant, the AUCs for bupropion and hydroxybupropion were more variable and tended to be

- 112 greater (by 53% to 57%) in patients with alcoholic liver disease. The differences in half-life for
- bupropion and the other metabolites in the 2 patient groups were minimal.

- 114 The second study showed no statistically significant differences in the pharmacokinetics of
- bupropion and its active metabolites in 9 patients with mild to moderate hepatic cirrhosis
- 116 compared to 8 healthy volunteers. However, more variability was observed in some of the
- 117 pharmacokinetic parameters for bupropion (AUC, C_{max} , and T_{max}) and its active metabolites ($t_{1/2}$)
- 118 in patients with mild to moderate hepatic cirrhosis. In addition, in patients with severe hepatic
- 119 cirrhosis, the bupropion C_{max} and AUC were substantially increased (mean difference: by
- approximately 70% and 3-fold, respectively) and more variable when compared to values in
- 121 healthy volunteers; the mean bupropion half-life was also longer (29 hours in patients with
- severe hepatic cirrhosis vs. 19 hours in healthy subjects). For the metabolite hydroxybupropion,
- 123 the mean C_{max} was approximately 69% lower. For the combined amino-alcohol isomers
- 124 threohydrobupropion and erythrohydrobupropion, the mean C_{max} was approximately 31% lower.
- 125 The mean AUC increased by about $1\frac{1}{2}$ -fold for hydroxybupropion and about $2\frac{1}{2}$ -fold for
- 126 three/erythrohydrobupropion. The median T_{max} was observed 19 hours later for
- 127 hydroxybupropion and 31 hours later for threo/erythrohydrobupropion. The mean half-lives for
- 128 hydroxybupropion and threo/erythrohydrobupropion were increased 5- and 2-fold, respectively,
- 129 in patients with severe hepatic cirrhosis compared to healthy volunteers (see WARNINGS,

130 PRECAUTIONS, and DOSAGE AND ADMINISTRATION).

- **Renal:** There is limited information on the pharmacokinetics of bupropion in patients with
 renal impairment. The elimination of the major metabolites of bupropion may be reduced by
 impaired renal function (see PRECAUTIONS: Renal Impairment).
- Left Ventricular Dysfunction: During a chronic dosing study with bupropion in
 14 depressed patients with left ventricular dysfunction (history of CHF or an enlarged heart on
 x-ray), no apparent effect on the pharmacokinetics of bupropion or its metabolites was revealed,
 compared to healthy volunteers.
- 138 Age: The effects of age on the pharmacokinetics of bupropion and its metabolites have not 139 been fully characterized, but an exploration of steady-state bupropion concentrations from several depression efficacy studies involving patients dosed in a range of 300 to 750 mg/day, on 140 141 a 3 times daily schedule, revealed no relationship between age (18 to 83 years) and plasma 142 concentration of bupropion. A single-dose pharmacokinetic study demonstrated that the 143 disposition of bupropion and its metabolites in elderly subjects was similar to that of younger 144 subjects. These data suggest there is no prominent effect of age on bupropion concentration; 145 however, another pharmacokinetic study, single and multiple dose, has suggested that the elderly
- 146 are at increased risk for accumulation of bupropion and its metabolites (see PRECAUTIONS:
- 147 Geriatric Use).
- 148 *Gender:* A single-dose study involving 12 healthy male and 12 healthy female volunteers
 149 revealed no sex-related differences in the pharmacokinetic parameters of bupropion.
- 150 **Smokers:** The effects of cigarette smoking on the pharmacokinetics of bupropion were
- studied in 34 healthy male and female volunteers; 17 were chronic cigarette smokers and 17
- 152 were nonsmokers. Following oral administration of a single 150-mg dose of bupropion, there

- 153 was no statistically significant difference in C_{max} , half-life, T_{max} , AUC, or clearance of bupropion
- 154 or its active metabolites between smokers and nonsmokers.

155 CLINICAL TRIALS

The efficacy of the immediate-release formulation of bupropion as a treatment for depression 156 was established in two 4-week, placebo-controlled trials in adult inpatients with depression and 157 158 in one 6-week, placebo-controlled trial in adult outpatients with depression. In the first study, 159 patients were titrated in a bupropion dose range of 300 to 600 mg/day on a 3 times daily 160 schedule; 78% of patients received maximum doses of 450 mg/day or less. This trial 161 demonstrated the effectiveness of the immediate-release formulation of bupropion on the 162 Hamilton Depression Rating Scale (HDRS) total score, the depressed mood item (item 1) from 163 that scale, and the Clinical Global Impressions (CGI) severity score. A second study included 164 2 fixed doses of the immediate-release formulation of bupropion (300 and 450 mg/day) and 165 placebo. This trial demonstrated the effectiveness of the immediate-release formulation of 166 bupropion, but only at the 450-mg/day dose; the results were positive for the HDRS total score 167 and the CGI severity score, but not for HDRS item 1. In the third study, outpatients received 168 300 mg/day of the immediate-release formulation of bupropion. This study demonstrated the 169 effectiveness of the immediate-release formulation of bupropion on the HDRS total score, HDRS 170 item 1, the Montgomery-Asberg Depression Rating Scale, the CGI severity score, and the CGI 171 improvement score.

Although there are not as yet independent trials demonstrating the antidepressant effectiveness of the sustained-release formulation of bupropion, studies have demonstrated the bioequivalence of the immediate-release and sustained-release forms of bupropion under steady-state conditions, i.e., bupropion sustained-release 150 mg twice daily was shown to be bioequivalent to 100 mg times daily of the immediate-release formulation of bupropion, with regard to both rate and extent of absorption, for parent drug and metabolites.

178 In a longer-term study, outpatients meeting DSM-IV criteria for major depressive disorder, 179 recurrent type, who had responded during an 8-week open trial on WELLBUTRIN SR (150 mg 180 twice daily) were randomized to continuation of their same WELLBUTRIN SR dose or placebo, 181 for up to 44 weeks of observation for relapse. Response during the open phase was defined as 182 CGI Improvement score of 1 (very much improved) or 2 (much improved) for each of the final 183 3 weeks. Relapse during the double-blind phase was defined as the investigator's judgment that 184 drug treatment was needed for worsening depressive symptoms. Patients receiving continued 185 WELLBUTRIN SR treatment experienced significantly lower relapse rates over the subsequent 186 44 weeks compared to those receiving placebo.

187 INDICATIONS AND USAGE

- 188 WELLBUTRIN SR is indicated for the treatment of major depressive disorder.
- 189 The efficacy of bupropion in the treatment of a major depressive episode was established in
- 190 two 4-week controlled trials of depressed inpatients and in one 6-week controlled trial of
- 191 depressed outpatients whose diagnoses corresponded most closely to the Major Depression

- 192 category of the APA Diagnostic and Statistical Manual (DSM) (see CLINICAL
- 193 PHARMACOLOGY).
- A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss
- 195 of interest or pleasure; in addition, at least 5 of the following symptoms have been present during
- 196 the same 2-week period and represent a change from previous functioning: depressed mood,
- 197 markedly diminished interest or pleasure in usual activities, significant change in weight and/or
- appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue,
- 199 feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt200 or suicidal ideation.
- 201 The efficacy of WELLBUTRIN SR in maintaining an antidepressant response for up to
- 202 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial
- 203 (see CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use
- 204 WELLBUTRIN SR for extended periods should periodically reevaluate the long-term usefulness
- 205 of the drug for the individual patient.

206 CONTRAINDICATIONS

- 207 WELLBUTRIN SR is contraindicated in patients with a seizure disorder.
- 208 WELLBUTRIN SR is contraindicated in patients treated with ZYBAN[®] (bupropion
- 209 hydrochloride) Sustained-Release Tablets; WELLBUTRIN[®] (bupropion hydrochloride), the
- 210 immediate-release formulation; WELLBUTRIN XL[®] (bupropion hydrochloride), the extended-
- 211 release formulation; or any other medications that contain bupropion because the incidence of
- 212 seizure is dose dependent.
- 213 WELLBUTRIN SR is contraindicated in patients with a current or prior diagnosis of bulimia 214 or anorexia nervosa because of a higher incidence of seizures noted in patients treated for
- 215 bulimia with the immediate-release formulation of bupropion.
- 216 WELLBUTRIN SR is contraindicated in patients undergoing abrupt discontinuation of 217 alcohol or sedatives (including benzodiazepines).
- 218 The concurrent administration of WELLBUTRIN SR Tablets and a monoamine oxidase
- 219 (MAO) inhibitor is contraindicated. At least 14 days should elapse between discontinuation of an
- 220 MAO inhibitor and initiation of treatment with WELLBUTRIN SR Tablets.
- 221 WELLBUTRIN SR is contraindicated in patients who have shown an allergic response to
- 222 bupropion or the other ingredients that make up WELLBUTRIN SR Tablets.

223 WARNINGS

- 224 Clinical Worsening and Suicide Risk: Patients with major depressive disorder (MDD),
- both adult and pediatric, may experience worsening of their depression and/or the emergence of
- suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they
- are taking antidepressant medications, and this risk may persist until significant remission
- 228 occurs. There has been a long-standing concern that antidepressants may have a role in inducing
- 229 worsening of depression and the emergence of suicidality in certain patients. Antidepressants

increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children

and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders.

Pooled analyses of short-term placebo-controlled trials of 9 antidepressant drugs (SSRIs and

- others) in children and adolescents with MDD, OCD, or other psychiatric disorders (a total of
- 234 24 trials involving over 4,400 patients) have revealed a greater risk of adverse events
- representing suicidal behavior or thinking (suicidality) during the first few months of treatment
- in those receiving antidepressants. The average risk of such events in patients receiving
 antidepressants was 4%, twice the placebo risk of 2%. There was considerable variation in risk
- among drugs, but a tendency toward an increase for almost all drugs studied. The risk of
- suicidality was most consistently observed in the MDD trials, but there were signals of risk
- 240 arising from some trials in other psychiatric indications (obsessive compulsive disorder and
- social anxiety disorder) as well. No suicides occurred in any of these trials. It is unknown
- 242 whether the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several
- 243 months. It is also unknown whether the suicidality risk extends to adults.
- All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Such observation would generally include at least weekly face-to-face contact with patients or their family members or caregivers during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may
- 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may
 be appropriate between face-to-face visits.
- Adults with MDD or co-morbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.
- In addition, patients with a history of suicidal behavior or thoughts, those patients
 exhibiting a significant degree of suicidal ideation prior to commencement of treatment,
 and young adults, are at an increased risk of suicidal thoughts or suicide attempts, and
 should receive careful monitoring during treatment.
- The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility,
 aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have
 been reported in adult and pediatric patients being treated with antidepressants for major
- 263 depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.
- Although a causal link between the emergence of such symptoms and either the worsening of
- 265 depression and/or the emergence of suicidal impulses has not been established, there is concern
- that such symptoms may represent precursors to emerging suicidality.
- 267 Consideration should be given to changing the therapeutic regimen, including possibly
- discontinuing the medication, in patients whose depression is persistently worse, or who are
- 269 experiencing emergent suicidality or symptoms that might be precursors to worsening depression

- or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.
- 272 Families and caregivers of pediatric patients being treated with antidepressants for
- 273 major depressive disorder or other indications, both psychiatric and nonpsychiatric,
- should be alerted about the need to monitor patients for the emergence of agitation,
- 275 irritability, unusual changes in behavior, and the other symptoms described above, as well
- as the emergence of suicidality, and to report such symptoms immediately to health care
- 277 providers. Such monitoring should include daily observation by families and caregivers.
- 278 Prescriptions for WELLBUTRIN SR should be written for the smallest quantity of tablets
- consistent with good patient management, in order to reduce the risk of overdose. Families andcaregivers of adults being treated for depression should be similarly advised.
- 281 Screening Patients for Bipolar Disorder: A major depressive episode may be the initial
- 282 presentation of bipolar disorder. It is generally believed (though not established in controlled
- trials) that treating such an episode with an antidepressant alone may increase the likelihood of
- 284 precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the
- symptoms described above represent such a conversion is unknown. However, prior to initiating
- treatment with an antidepressant, patients with depressive symptoms should be adequately
- screened to determine if they are at risk for bipolar disorder; such screening should include a
- detailed psychiatric history, including a family history of suicide, bipolar disorder, and
- depression. It should be noted that WELLBUTRIN SR is not approved for use in treating bipolardepression.
- Patients should be made aware that WELLBUTRIN SR contains the same active
 ingredient found in ZYBAN, used as an aid to smoking cessation treatment, and that
 WELLBUTRIN SR should not be used in combination with ZYBAN, or any other
 medications that contain bupropion, such as WELLBUTRIN (bupropion hydrochloride),
 the immediate-release formulation or WELLBUTRIN XL (bupropion hydrochloride), the
 extended-release formulation.
- 297
- 298 **Seizures:** Bupropion is associated with a dose-related risk of seizures. The risk of seizures 299 is also related to patient factors, clinical situations, and concomitant medications, which
- 300 must be considered in selection of patients for therapy with WELLBUTRIN SR.
- 301 WELLBUTRIN SR should be discontinued and not restarted in patients who experience a 302 seizure while on treatment.
- Dose: At doses of WELLBUTRIN SR up to a dose of 300 mg/day, the incidence of
 seizure is approximately 0.1% (1/1,000) and increases to approximately 0.4% (4/1,000)
 at the maximum recommended dose of 400 mg/day.
- 306 Data for the immediate-release formulation of bupropion revealed a seizure incidence
- 307 of approximately 0.4% (i.e., 13 of 3,200 patients followed prospectively) in patients
- 308 treated at doses in a range of 300 to 450 mg/day. The 450-mg/day upper limit of this
- 309 dose range is close to the currently recommended maximum dose of 400 mg/day for

- 310 WELLBUTRIN SR Tablets. This seizure incidence (0.4%) may exceed that of other 311 marketed antidepressants and WELLBUTRIN SR Tablets up to 300 mg/day by as
- much as 4-fold. This relative risk is only an approximate estimate because no direct
- 313 comparative studies have been conducted.
- 314 Additional data accumulated for the immediate-release formulation of bupropion
- 315 suggested that the estimated seizure incidence increases almost tenfold between 450 and
- 316 **600 mg/day, which is twice the usual adult dose and one-half the maximum**
- 317 recommended daily dose (400 mg) of WELLBUTRIN SR Tablets. This
- disproportionate increase in seizure incidence with dose incrementation calls for
 caution in dosing.
- 320 Data for WELLBUTRIN SR Tablets revealed a seizure incidence of approximately 321 0.1% (i.e., 3 of 3,100 patients followed prospectively) in patients treated at doses in a 322 range of 100 to 300 mg/day. It is not possible to know if the lower seizure incidence 323 observed in this study involving the sustained-release formulation of bupropion 324 resulted from the different formulation or the lower dose used. However, as noted 325 above, the immediate-release and sustained-release formulations are bioequivalent with 326 regard to both rate and extent of absorption during steady state (the most pertinent 327 condition to estimating seizure incidence), since most observed seizures occur under 328 steady-state conditions.
- Patient factors: Predisposing factors that may increase the risk of seizure with
 bupropion use include history of head trauma or prior seizure, central nervous system
 (CNS) tumor, the presence of severe hepatic cirrhosis, and concomitant medications
 that lower seizure threshold.
- Clinical situations: Circumstances associated with an increased seizure risk include,
 among others, excessive use of alcohol or sedatives (including benzodiazepines);
 addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and
 anorectics; and diabetes treated with oral hypoglycemics or insulin.
- Concomitant medications: Many medications (e.g., antipsychotics, antidepressants,
 theophylline, systemic steroids) are known to lower seizure threshold.

Recommendations for Reducing the Risk of Seizure: Retrospective analysis of
 clinical experience gained during the development of bupropion suggests that the risk of
 seizure may be minimized if

- the total daily dose of WELLBUTRIN SR Tablets does *not* exceed 400 mg,
- the daily dose is administered twice daily, and
- the rate of incrementation of dose is gradual.
- No single dose should exceed 200 mg to avoid high peak concentrations of bupropion
 and/or its metabolites.
- 347 WELLBUTRIN SR should be administered with extreme caution to patients with a
- 348 history of seizure, cranial trauma, or other predisposition(s) toward seizure, or patients

- 349 treated with other agents (e.g., antipsychotics, other antidepressants, theophylline, systemic
- 350 steroids, etc.) that lower seizure threshold.
- 351 Hepatic Impairment: WELLBUTRIN SR should be used with extreme caution in patients
- 352 with severe hepatic cirrhosis. In these patients a reduced frequency and/or dose is required,
- as peak bupropion, as well as AUC, levels are substantially increased and accumulation is
- 354 likely to occur in such patients to a greater extent than usual. The dose should not exceed
- 355 100 mg every day or 150 mg every other day in these patients (see CLINICAL
- 356 PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).
- 357 **Potential for Hepatotoxicity:** In rats receiving large doses of bupropion chronically, there
- 358 was an increase in incidence of hepatic hyperplastic nodules and hepatocellular hypertrophy. In
- 359 dogs receiving large doses of bupropion chronically, various histologic changes were seen in the
- 360 liver, and laboratory tests suggesting mild hepatocellular injury were noted.

361 **PRECAUTIONS**

- 362 General: Agitation and Insomnia: Patients in placebo-controlled trials with
- 363 WELLBUTRIN SR Tablets experienced agitation, anxiety, and insomnia as shown in Table 1.
- 364

365 Table 1. Incidence of Agitation, Anxiety, and Insomnia in Placebo-Controlled Trials

	WELLBUTRIN SR	WELLBUTRIN SR		
	300 mg/day	400 mg/day	Placebo	
Adverse Event Term	(n = 376)	(n = 114)	(n = 385)	
Agitation	3%	9%	2%	
Anxiety	5%	6%	3%	
Insomnia	11%	16%	6%	

366

367 In clinical studies, these symptoms were sometimes of sufficient magnitude to require

- 368 treatment with sedative/hypnotic drugs.
- Symptoms were sufficiently severe to require discontinuation of treatment in 1% and 2.6% of
 patients treated with 300 and 400 mg/day, respectively, of WELLBUTRIN SR Tablets and 0.8%
- 371 of patients treated with placebo.
- 372 Psychosis, Confusion, and Other Neuropsychiatric Phenomena: Depressed

373 patients treated with an immediate-release formulation of bupropion or with WELLBUTRIN SR

- Tablets have been reported to show a variety of neuropsychiatric signs and symptoms, including
- delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. In some
 cases, these symptoms abated upon dose reduction and/or withdrawal of treatment.
- Activation of Psychosis and/or Mania: Antidepressants can precipitate manic episodes
 in bipolar disorder patients during the depressed phase of their illness and may activate latent
 psychosis in other susceptible patients. WELLBUTRIN SR is expected to pose similar risks.
- 3/9 psychosis in other susceptible patients. WELLBUTKIN SK is expected to pose similar risks.
- Altered Appetite and Weight: In placebo-controlled studies, patients experienced weight
 gain or weight loss as shown in Table 2.

382

383	Table 2. Incidence of Weight Gain and Weight Loss in Placebo-Controlled Trials
505	Tuble 2. Incluence of Weight Guin and Weight Loss in Theebo Controlled Thats

	WELLBUTRIN SR	WELLBUTRIN SR	
	300 mg/day	400 mg/day	Placebo
Weight Change	(n = 339)	(n = 112)	(n = 347)
Gained >5 lbs	3%	2%	4%
Lost >5 lbs	14%	19%	6%

384

In studies conducted with the immediate-release formulation of bupropion, 35% of patients receiving tricyclic antidepressants gained weight, compared to 9% of patients treated with the immediate-release formulation of bupropion. If weight loss is a major presenting sign of a

388 patient's depressive illness, the anorectic and/or weight-reducing potential of

389 WELLBUTRIN SR Tablets should be considered.

Allergic Reactions: Anaphylactoid/anaphylactic reactions characterized by symptoms such as pruritus, urticaria, angioedema, and dyspnea requiring medical treatment have been reported in clinical trials with bupropion. In addition, there have been rare spontaneous postmarketing reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock associated with bupropion. A patient should stop taking WELLBUTRIN SR and consult a doctor if experiencing allergic or anaphylactoid/anaphylactic reactions (e.g., skin rash, pruritus, hives, chest pain, edema, and shortness of breath) during treatment.

Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed
 hypersensitivity have been reported in association with bupropion. These symptoms may
 resemble serum sickness.

400 **Cardiovascular Effects:** In clinical practice, hypertension, in some cases severe, requiring 401 acute treatment, has been reported in patients receiving bupropion alone and in combination with 402 nicotine replacement therapy. These events have been observed in both patients with and without 403 evidence of preexisting hypertension.

404 Data from a comparative study of the sustained-release formulation of bupropion (ZYBAN[®]

405 Sustained-Release Tablets), nicotine transdermal system (NTS), the combination of sustained-

406 release bupropion plus NTS, and placebo as an aid to smoking cessation suggest a higher

407 incidence of treatment-emergent hypertension in patients treated with the combination of

408 sustained-release bupropion and NTS. In this study, 6.1% of patients treated with the

409 combination of sustained-release bupropion and NTS had treatment-emergent hypertension

410 compared to 2.5%, 1.6%, and 3.1% of patients treated with sustained-release bupropion, NTS,

411 and placebo, respectively. The majority of these patients had evidence of preexisting

412 hypertension. Three patients (1.2%) treated with the combination of ZYBAN and NTS and

413 1 patient (0.4%) treated with NTS had study medication discontinued due to hypertension

414 compared to none of the patients treated with ZYBAN or placebo. Monitoring of blood pressure

415 is recommended in patients who receive the combination of bupropion and nicotine replacement.

- 416 There is no clinical experience establishing the safety of WELLBUTRIN SR Tablets in
- 417 patients with a recent history of myocardial infarction or unstable heart disease. Therefore, care
- 418 should be exercised if it is used in these groups. Bupropion was well tolerated in depressed
- 419 patients who had previously developed orthostatic hypotension while receiving tricyclic
- 420 antidepressants, and was also generally well tolerated in a group of 36 depressed inpatients with
- 421 stable congestive heart failure (CHF). However, bupropion was associated with a rise in supine
- 422 blood pressure in the study of patients with CHF, resulting in discontinuation of treatment in
- 423 2 patients for exacerbation of baseline hypertension.
- Hepatic Impairment: WELLBUTRIN SR should be used with extreme caution in patients
 with severe hepatic cirrhosis. In these patients, a reduced frequency and/or dose is required.
 WELLBUTRIN SR should be used with caution in patients with hepatic impairment (including
 mild to moderate hepatic cirrhosis) and reduced frequency and/or dose should be considered in
 patients with mild to moderate hepatic cirrhosis.
- 429 All patients with hepatic impairment should be closely monitored for possible adverse effects 430 that could indicate high drug and metabolite levels (see CLINICAL PHARMACOLOGY,
- 431 WARNINGS, and DOSAGE AND ADMINISTRATION).
- 432 *Renal Impairment:* There is limited information on the pharmacokinetics of bupropion in
 433 patients with renal impairment. Bupropion is extensively metabolized in the liver to active
 434 metabolites, which are further metabolized and subsequently excreted by the kidneys.
- 435 WELLBUTRIN SR should be used with caution in patients with renal impairment and a reduced
- 436 frequency and/or dose should be considered as the metabolites of bupropion may accumulate in
- 437 such patients to a greater extent than usual. The patient should be closely monitored for possible438 adverse effects that could indicate high drug or metabolite levels.
- 439 Information for Patients: Prescribers or other health professionals should inform patients,
- their families, and their caregivers about the benefits and risks associated with treatment with
- 441 WELLBUTRIN SR and should counsel them in its appropriate use. A patient Medication Guide
- About Using Antidepressants in Children and Teenagers is available for WELLBUTRIN SR.
- 443 The prescriber or health professional should instruct patients, their families, and their caregivers
- to read the Medication Guide and should assist them in understanding its contents. Patients
- should be given the opportunity to discuss the contents of the Medication Guide and to obtain
- answers to any questions they may have. The complete text of the Medication Guide is reprinted
- 447 at the end of this document. Additional important information concerning WELLBUTRIN SR is
- 448 provided in a tear-off leaflet entitled "Patient Information" at the end of this labeling.
- 449 Patients should be advised of the following issues and asked to alert their prescriber if these450 occur while taking WELLBUTRIN SR.
- 451 *Clinical Worsening and Suicide Risk:* Patients, their families, and their caregivers
- 452 should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia,
- 453 irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness),
- 454 hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal
- 455 ideation, especially early during antidepressant treatment and when the dose is adjusted up or

456 down. Families and caregivers of patients should be advised to observe for the emergence of

- 457 such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be
- 458 reported to the patient's prescriber or health professional, especially if they are severe, abrupt in

459 onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be

associated with an increased risk for suicidal thinking and behavior and indicate a need for very

461 close monitoring and possibly changes in the medication.

462 Patients should be made aware that WELLBUTRIN SR contains the same active ingredient

found in ZYBAN, used as an aid to smoking cessation treatment, and that WELLBUTRIN SR
 should not be used in combination with ZYBAN or any other medications that contain bupropion

should not be used in combination with ZYBAN or any other medications that contain bupropion
 hydrochloride (such as WELLBUTRIN, the immediate-release formulation and WELLBUTRIN

466 XL, the extended-release formulation).

As dose is increased during initial titration to doses above 150 mg/day, patients should be
instructed to take WELLBUTRIN SR Tablets in 2 divided doses, preferably with at least 8 hours
between successive doses, to minimize the risk of seizures.

470 Patients should be told that WELLBUTRIN SR should be discontinued and not restarted if471 they experience a seizure while on treatment.

472 Patients should be told that any CNS-active drug like WELLBUTRIN SR Tablets may impair

their ability to perform tasks requiring judgment or motor and cognitive skills. Consequently,

474 until they are reasonably certain that WELLBUTRIN SR Tablets do not adversely affect their

475 performance, they should refrain from driving an automobile or operating complex, hazardous476 machinery.

Patients should be told that the excessive use or abrupt discontinuation of alcohol or sedatives
(including benzodiazepines) may alter the seizure threshold. Some patients have reported lower
alcohol tolerance during treatment with WELLBUTRIN SR. Patients should be advised that the
consumption of alcohol should be minimized or avoided.

481 Patients should be advised to inform their physicians if they are taking or plan to take any

482 prescription or over-the-counter drugs. Concern is warranted because WELLBUTRIN SR
483 Tablets and other drugs may affect each other's metabolism.

Patients should be advised to notify their physicians if they become pregnant or intend to
become pregnant during therapy.

Patients should be advised to swallow WELLBUTRIN SR Tablets whole so that the release
rate is not altered. Do not chew, divide, or crush tablets.

488 **Laboratory Tests:** There are no specific laboratory tests recommended.

489 **Drug Interactions:** Few systemic data have been collected on the metabolism of bupropion

490 following concomitant administration with other drugs or, alternatively, the effect of

491 concomitant administration of bupropion on the metabolism of other drugs.

492 Because bupropion is extensively metabolized, the coadministration of other drugs may affect

493 its clinical activity. In vitro studies indicate that bupropion is primarily metabolized to

494 hydroxybupropion by the CYP2B6 isoenzyme. Therefore, the potential exists for a drug

495 interaction between WELLBUTRIN SR and drugs that are substrates or inhibitors of the

496 CYP2B6 isoenzyme (e.g., orphenadrine, thiotepa, and cyclophosphamide). In addition, in vitro

- 497 studies suggest that paroxetine, sertraline, norfluoxetine, and fluvoxamine as well as nelfinavir,
- 498 ritonavir, and efavirenz inhibit the hydroxylation of bupropion. No clinical studies have been
- 499 performed to evaluate this finding. The threohydrobupropion metabolite of bupropion does not
- appear to be produced by the cytochrome P450 isoenzymes. The effects of concomitant
- administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites
- 502 were studied in 24 healthy young male volunteers. Following oral administration of two 150-mg

503 WELLBUTRIN SR Tablets with and without 800 mg of cimetidine, the pharmacokinetics of

- 504 bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases
- in the AUC and C_{max} , respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
- 507 While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., 508 carbamazepine, phenobarbital, phenytoin).
- 509 Multiple oral doses of bupropion had no statistically significant effects on the single dose
- 510 pharmacokinetics of lamotrigine in 12 healthy volunteers and was associated with a slight 511 increase in the AUC (15%) of lamotriging glugurenide
- 511 increase in the AUC (15%) of lamotrigine glucuronide.
- 512 Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in 513 humans. In one study, following chronic administration of bupropion, 100 mg 3 times daily to
- 514 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism.
- 515 Nevertheless, there may be the potential for clinically important alterations of blood levels of
- 516 coadministered drugs.
- 517 Drugs Metabolized By Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are 518 519 metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this 520 isoenzyme, bupropion and hydroxybupropion are inhibitors of CYP2D6 isoenzyme in vitro. In a 521 study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 522 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 523 50 mg desipramine increased the C_{max} , AUC, and $t_{1/2}$ of desipramine by an average of 524 approximately 2-, 5-, and 2-fold, respectively. The effect was present for at least 7 days after the
- 525 last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6
- 526 has not been formally studied.
- 527 Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6
- 528 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,
- 529 paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine),
- beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide),
- should be approached with caution and should be initiated at the lower end of the dose range of
- the concomitant medication. If bupropion is added to the treatment regimen of a patient already
- receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original
- medication should be considered, particularly for those concomitant medications with a narrow
- 535 therapeutic index.

536 **MAO** Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is 537 enhanced by the MAO inhibitor phenelzine (see CONTRAINDICATIONS). 538 Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse 539 experiences in patients receiving bupropion concurrently with either levodopa or amantadine. 540 Administration of WELLBUTRIN SR Tablets to patients receiving either levodopa or 541 amantadine concurrently should be undertaken with caution, using small initial doses and 542 gradual dose increases. 543 Drugs That Lower Seizure Threshold: Concurrent administration of 544 WELLBUTRIN SR Tablets and agents (e.g., antipsychotics, other antidepressants, theophylline, 545 systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme 546 caution (see WARNINGS). Low initial dosing and gradual dose increases should be employed. 547 Nicotine Transdermal System: (see PRECAUTIONS: Cardiovascular Effects). 548 **Alcohol:** In postmarketing experience, there have been rare reports of adverse 549 neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol 550 during treatment with WELLBUTRIN SR. The consumption of alcohol during treatment with 551 WELLBUTRIN SR should be minimized or avoided (also see CONTRAINDICATIONS). 552 Carcinogenesis, Mutagenesis, Impairment of Fertility: Lifetime carcinogenicity studies 553 were performed in rats and mice at doses up to 300 and 150 mg/kg/day, respectively. These 554 doses are approximately 7 and 2 times the maximum recommended human dose (MRHD), respectively, on a mg/m² basis. In the rat study there was an increase in nodular proliferative 555 lesions of the liver at doses of 100 to 300 mg/kg/day (approximately 2 to 7 times the MRHD on a 556 557 mg/m^2 basis); lower doses were not tested. The question of whether or not such lesions may be precursors of neoplasms of the liver is currently unresolved. Similar liver lesions were not seen 558 559 in the mouse study, and no increase in malignant tumors of the liver and other organs was seen in 560 either study. 561 Bupropion produced a positive response (2 to 3 times control mutation rate) in 2 of 5 strains in the Ames bacterial mutagenicity test and an increase in chromosomal aberrations in 1 of 3 in 562 563 vivo rat bone marrow cytogenetic studies. 564 A fertility study in rats at doses up to 300 mg/kg/day revealed no evidence of impaired 565 fertility. **Pregnancy:** Teratogenic Effects: Pregnancy Category C. In studies conducted in rats and 566 567 rabbits, bupropion was administered orally at doses up to 450 and 150 mg/kg/day, respectively 568 (approximately 11 and 7 times the maximum recommended human dose [MRHD], respectively, 569 on a mg/m² basis), during the period of organogenesis. No clear evidence of teratogenic activity 570 was found in either species; however, in rabbits, slightly increased incidences of fetal 571 malformations and skeletal variations were observed at the lowest dose tested (25 mg/kg/day, 572 approximately equal to the MRHD on a mg/m² basis) and greater. Decreased fetal weights were

573 seen at 50 mg/kg and greater.

574 When rats were administered bupropion at oral doses of up to 300 mg/kg/day (approximately 575 7 times the MRHD on a mg/m² basis) prior to mating and throughout pregnancy and lactation,

576 there were no apparent adverse effects on offspring development.

577 One study has been conducted in pregnant women. This retrospective, managed-care database 578 study assessed the risk of congenital malformations overall, and cardiovascular malformations 579 specifically, following exposure to bupropion in the first trimester compared to the risk of these 580 malformations following exposure to other antidepressants in the first trimester and bupropion 581 outside of the first trimester. This study included 7,005 infants with antidepressant exposure

- 581 outside of the first trimester. This study included 7,005 infants with antidepressant exposure 582 during pregnancy, 1,213 of whom were exposed to bupropion in the first trimester. The study
- showed no greater risk for congenital malformations overall, or cardiovascular malformations
- 584 specifically, following first trimester bupropion exposure compared to exposure to all other
- antidepressants in the first trimester, or bupropion outside of the first trimester. The results of
- this study have not been corroborated. WELLBUTRIN SR should be used during pregnancy only
- 587 if the potential benefit justifies the potential risk to the fetus.

588 To monitor fetal outcomes of pregnant women exposed to WELLBUTRIN SR,

- 589 GlaxoSmithKline maintains a Bupropion Pregnancy Registry. Health care providers are
- encouraged to register patients by calling (800) 336-2176.
- Labor and Delivery: The effect of WELLBUTRIN SR Tablets on labor and delivery in
 humans is unknown.
- 593 **Nursing Mothers:** Like many other drugs, bupropion and its metabolites are secreted in human
- 594 milk. Because of the potential for serious adverse reactions in nursing infants from
- 595 WELLBUTRIN SR Tablets, a decision should be made whether to discontinue nursing or to
- 596 discontinue the drug, taking into account the importance of the drug to the mother.
- 597 **Pediatric Use:** Safety and effectiveness in the pediatric population have not been established
- 598 (see BOX WARNING and WARNINGS: Clinical Worsening and Suicide Risk). Anyone
- considering the use of WELLBUTRIN SR in a child or adolescent must balance the potentialrisks with the clinical need.
- 601 **Geriatric Use:** Of the approximately 6,000 patients who participated in clinical trials with
- 602 bupropion sustained-release tablets (depression and smoking cessation studies), 275 were 65 and
- 603 over and 47 were 75 and over. In addition, several hundred patients 65 and over participated in
- 604 clinical trials using the immediate-release formulation of bupropion (depression studies). No
- 605 overall differences in safety or effectiveness were observed between these subjects and younger
- 606 subjects, and other reported clinical experience has not identified differences in responses
- 607 between the elderly and younger patients, but greater sensitivity of some older individuals cannot608 be ruled out.
- A single-dose pharmacokinetic study demonstrated that the disposition of bupropion and its
- 610 metabolites in elderly subjects was similar to that of younger subjects; however, another
- 611 pharmacokinetic study, single and multiple dose, has suggested that the elderly are at increased
- 612 risk for accumulation of bupropion and its metabolites (see CLINICAL PHARMACOLOGY).

- 613 Bupropion is extensively metabolized in the liver to active metabolites, which are further
- 614 metabolized and excreted by the kidneys. The risk of toxic reaction to this drug may be greater in
- 615 patients with impaired renal function. Because elderly patients are more likely to have decreased
- 616 renal function, care should be taken in dose selection, and it may be useful to monitor renal
- 617 function (see PRECAUTIONS: Renal Impairment and DOSAGE AND ADMINISTRATION).

618 **ADVERSE REACTIONS** (See also WARNINGS and PRECAUTIONS.)

- 619 The information included under the Incidence in Controlled Trials subsection of ADVERSE
- 620 REACTIONS is based primarily on data from controlled clinical trials with WELLBUTRIN SR
- 621 Tablets. Information on additional adverse events associated with the sustained-release
- 622 formulation of bupropion in smoking cessation trials, as well as the immediate-release
- 623 formulation of bupropion, is included in a separate section (see Other Events Observed During
- 624 the Clinical Development and Postmarketing Experience of Bupropion).
- 625 Incidence in Controlled Trials With WELLBUTRIN SR: Adverse Events Associated

626 With Discontinuation of Treatment Among Patients Treated With

627 WELLBUTRIN SR Tablets: In placebo-controlled clinical trials, 9% and 11% of patients

- 628 treated with 300 and 400 mg/day, respectively, of WELLBUTRIN SR Tablets and 4% of patients
- 629 treated with placebo discontinued treatment due to adverse events. The specific adverse events in
- 630 these trials that led to discontinuation in at least 1% of patients treated with either 300 or
- 631 400 mg/day of WELLBUTRIN SR Tablets and at a rate at least twice the placebo rate are listed
- 632 in Table 3.
- 633

634 Table 3. Treatment Discontinuations Due to Adverse Events in Placebo-Controlled Trials

	WELLBUTRIN SR	WELLBUTRIN SR	
	300 mg/day	400 mg/day	Placebo
Adverse Event Term	(n = 376)	(n = 114)	(n = 385)
Rash	2.4%	0.9%	0.0%
Nausea	0.8%	1.8%	0.3%
Agitation	0.3%	1.8%	0.3%
Migraine	0.0%	1.8%	0.3%

635

636 Adverse Events Occurring at an Incidence of 1% or More Among Patients

637 Treated With WELLBUTRIN SR Tablets: Table 4 enumerates treatment-emergent adverse

638 events that occurred among patients treated with 300 and 400 mg/day of WELLBUTRIN SR 639

- Tablets and with placebo in placebo-controlled trials. Events that occurred in either the 300- or
- 640 400-mg/day group at an incidence of 1% or more and were more frequent than in the placebo
- 641 group are included. Reported adverse events were classified using a COSTART-based
- 642 Dictionary.
- 643 Accurate estimates of the incidence of adverse events associated with the use of any drug are 644 difficult to obtain. Estimates are influenced by drug dose, detection technique, setting, physician

- 645 judgments, etc. The figures cited cannot be used to predict precisely the incidence of untoward
- 646 events in the course of usual medical practice where patient characteristics and other factors
- 647 differ from those that prevailed in the clinical trials. These incidence figures also cannot be
- 648 compared with those obtained from other clinical studies involving related drug products as each
- 649 group of drug trials is conducted under a different set of conditions.
- 650 Finally, it is important to emphasize that the tabulation does not reflect the relative severity
- and/or clinical importance of the events. A better perspective on the serious adverse events
- associated with the use of WELLBUTRIN SR Tablets is provided in the WARNINGS and
- 653 PRECAUTIONS sections.
- 654

	WELLBUTRIN SR	WELLBUTRIN SR	-
Body System/	300 mg/day	400 mg/day	Placebo
Adverse Event	(n = 376)	(n = 114)	(n = 385)
Body (General)			
Headache	26%	25%	23%
Infection	8%	9%	6%
Abdominal pain	3%	9%	2%
Asthenia	2%	4%	2%
Chest pain	3%	4%	1%
Pain	2%	3%	2%
Fever	1%	2%	
Cardiovascular			
Palpitation	2%	6%	2%
Flushing	1%	4%	
Migraine	1%	4%	1%
Hot flashes	1%	3%	1%
Digestive			
Dry mouth	17%	24%	7%
Nausea	13%	18%	8%
Constipation	10%	5%	7%
Diarrhea	5%	7%	6%
Anorexia	5%	3%	2%
Vomiting	4%	2%	2%
Dysphagia	0%	2%	0%
Musculoskeletal			
Myalgia	2%	6%	3%
Arthralgia	1%	4%	1%
Arthritis	0%	2%	0%
Twitch	1%	2%	

655 **Table 4. Treatment-Emergent Adverse Events in Placebo-Controlled Trials***

Nervous system			
Insomnia	11%	16%	6%
Dizziness	7%	11%	5%
Agitation	3%	9%	2%
Anxiety	5%	6%	3%
Tremor	6%	3%	1%
Nervousness	5%	3%	3%
Somnolence	2%	3%	2%
Irritability	3%	2%	2%
Memory decreased	_	3%	1%
Paresthesia	1%	2%	1%
Central nervous			
system stimulation	2%	1%	1%
Respiratory			
Pharyngitis	3%	11%	2%
Sinusitis	3%	1%	2%
Increased cough	1%	2%	1%
Skin			
Sweating	6%	5%	2%
Rash	5%	4%	1%
Pruritus	2%	4%	2%
Urticaria	2%	1%	0%
Special senses			
Tinnitus	6%	6%	2%
Taste perversion	2%	4%	
Amblyopia	3%	2%	2%
Urogenital			
Urinary frequency	2%	5%	2%
Urinary urgency		2%	0%
Vaginal hemorrhage ⁺	0%	2%	
Urinary tract	1%	0%	
infection			

^{*} Adverse events that occurred in at least 1% of patients treated with either 300 or 400 mg/day

657 of WELLBUTRIN SR Tablets, but equally or more frequently in the placebo group, were:

abnormal dreams, accidental injury, acne, appetite increased, back pain, bronchitis,

dysmenorrhea, dyspepsia, flatulence, flu syndrome, hypertension, neck pain, respiratory

660 disorder, rhinitis, and tooth disorder.

661 [†] Incidence based on the number of female patients.

662 — Hyphen denotes adverse events occurring in greater than 0 but less than 0.5% of patients.

663

Incidence of Commonly Observed Adverse Events in Controlled Clinical Trials: 664 665 Adverse events from Table 4 occurring in at least 5% of patients treated with 666 WELLBUTRIN SR Tablets and at a rate at least twice the placebo rate are listed below for the 667 300- and 400-mg/day dose groups. 668 WELLBUTRIN SR 300 mg/day: Anorexia, dry mouth, rash, sweating, tinnitus, and 669 tremor. 670 WELLBUTRIN SR 400 mg/day: Abdominal pain, agitation, anxiety, dizziness, dry 671 mouth, insomnia, myalgia, nausea, palpitation, pharyngitis, sweating, tinnitus, and urinary 672 frequency. 673 Other Events Observed During the Clinical Development and Postmarketing 674 **Experience of Bupropion:** In addition to the adverse events noted above, the following 675 events have been reported in clinical trials and postmarketing experience with the 676 sustained-release formulation of bupropion in depressed patients and in nondepressed smokers, 677 as well as in clinical trials and postmarketing clinical experience with the immediate-release 678 formulation of bupropion. 679 Adverse events for which frequencies are provided below occurred in clinical trials with the 680 sustained-release formulation of bupropion. The frequencies represent the proportion of patients 681 who experienced a treatment-emergent adverse event on at least one occasion in 682 placebo-controlled studies for depression (n = 987) or smoking cessation (n = 1.013), or patients 683 who experienced an adverse event requiring discontinuation of treatment in an open-label surveillance study with WELLBUTRIN SR Tablets (n = 3,100). All treatment-emergent adverse 684 685 events are included except those listed in Tables 1 through 4, those events listed in other 686 safety-related sections, those adverse events subsumed under COSTART terms that are either 687 overly general or excessively specific so as to be uninformative, those events not reasonably 688 associated with the use of the drug, and those events that were not serious and occurred in fewer 689 than 2 patients. Events of major clinical importance are described in the WARNINGS and 690 PRECAUTIONS sections of the labeling. 691 Events are further categorized by body system and listed in order of decreasing frequency 692 according to the following definitions of frequency: Frequent adverse events are defined as those 693 occurring in at least 1/100 patients. Infrequent adverse events are those occurring in 1/100 to 694 1/1,000 patients, while rare events are those occurring in less than 1/1,000 patients. 695 Adverse events for which frequencies are not provided occurred in clinical trials or 696 postmarketing experience with bupropion. Only those adverse events not previously listed for 697 sustained-release bupropion are included. The extent to which these events may be associated 698 with WELLBUTRIN SR is unknown. 699 Body (General): Infrequent were chills, facial edema, musculoskeletal chest pain, and 700 photosensitivity. Rare was malaise. Also observed were arthralgia, myalgia, and fever with rash 701 and other symptoms suggestive of delayed hypersensitivity. These symptoms may resemble 702 serum sickness (see PRECAUTIONS).

703 **Cardiovascular:** Infrequent were postural hypotension, stroke, tachycardia, and

vasodilation. Rare was syncope. Also observed were complete atrioventricular block,

extrasystoles, hypotension, hypertension (in some cases severe, see PRECAUTIONS),

706 myocardial infarction, phlebitis, and pulmonary embolism.

Digestive: Infrequent were abnormal liver function, bruxism, gastric reflux, gingivitis,
 glossitis, increased salivation, jaundice, mouth ulcers, stomatitis, and thirst. Rare was edema of
 tongue. Also observed were colitis, esophagitis, gastrointestinal hemorrhage, gum hemorrhage,
 hepatitis, intestinal perforation, liver damage, pancreatitis, and stomach ulcer.

Endocrine: Also observed were hyperglycemia, hypoglycemia, and syndrome of
 inappropriate antidiuretic hormone.

Hemic and Lymphatic: Infrequent was ecchymosis. Also observed were anemia,
 leukocytosis, leukopenia, lymphadenopathy, pancytopenia, and thrombocytopenia. Altered PT

and/or INR, infrequently associated with hemorrhagic or thrombotic complications, were

716 observed when bupropion was coadministered with warfarin.

717 *Metabolic and Nutritional:* Infrequent were edema and peripheral edema. Also observed
718 was glycosuria.

719 *Musculoskeletal:* Infrequent were leg cramps. Also observed were muscle
 720 rigidity/fever/rhabdomyolysis and muscle weakness.

721 *Nervous System:* Infrequent were abnormal coordination, decreased libido,

depersonalization, dysphoria, emotional lability, hostility, hyperkinesia, hypertonia, hypesthesia,

suicidal ideation, and vertigo. Rare were amnesia, ataxia, derealization, and hypomania. Also

observed were abnormal electroencephalogram (EEG), akinesia, aggression, aphasia, coma,

delirium, delusions, dysarthria, dyskinesia, dystonia, euphoria, extrapyramidal syndrome,

- hallucinations, hypokinesia, increased libido, manic reaction, neuralgia, neuropathy, paranoid
- 727 ideation, restlessness, and unmasking tardive dyskinesia.
- 728 **Respiratory:** Rare was bronchospasm. Also observed was pneumonia.
- 729 *Skin:* Rare was maculopapular rash. Also observed were alopecia, angioedema, exfoliative
 730 dermatitis, and hirsutism.

731 Special Senses: Infrequent were accommodation abnormality and dry eye. Also observed
 732 were deafness, diplopia, and mydriasis.

Urogenital: Infrequent were impotence, polyuria, and prostate disorder. Also observed were
 abnormal ejaculation, cystitis, dyspareunia, dysuria, gynecomastia, menopause, painful erection,
 salpingitis, urinary incontinence, urinary retention, and vaginitis.

755 saipingitis, urinary incontinence, urinary retention, and vag

736 DRUG ABUSE AND DEPENDENCE

- 737 **Controlled Substance Class:** Bupropion is not a controlled substance.
- 738 **Humans:** Controlled clinical studies of bupropion (immediate-release formulation) conducted
- in normal volunteers, in subjects with a history of multiple drug abuse, and in depressed patients
- showed some increase in motor activity and agitation/excitement.

- 741 In a population of individuals experienced with drugs of abuse, a single dose of 400 mg of
- bupropion produced mild amphetamine-like activity as compared to placebo on the
- 743 Morphine-Benzedrine Subscale of the Addiction Research Center Inventories (ARCI), and a
- score intermediate between placebo and amphetamine on the Liking Scale of the ARCI. These
- scales measure general feelings of euphoria and drug desirability.
- Findings in clinical trials, however, are not known to reliably predict the abuse potential of
- 747 drugs. Nonetheless, evidence from single-dose studies does suggest that the recommended daily
- dosage of bupropion when administered in divided doses is not likely to be especially reinforcing
- to amphetamine or stimulant abusers. However, higher doses that could not be tested because of
- the risk of seizure might be modestly attractive to those who abuse stimulant drugs.
- 751 **Animals:** Studies in rodents and primates have shown that bupropion exhibits some
- pharmacologic actions common to psychostimulants. In rodents, it has been shown to increase
- 753 locomotor activity, elicit a mild stereotyped behavioral response, and increase rates of
- responding in several schedule-controlled behavior paradigms. In primate models to assess the
- positive reinforcing effects of psychoactive drugs, bupropion was self-administered
- intravenously. In rats, bupropion produced amphetamine-like and cocaine-like discriminative
- stimulus effects in drug discrimination paradigms used to characterize the subjective effects of
- 758 psychoactive drugs.

759 **OVERDOSAGE**

- 760 **Human Overdose Experience:** Overdoses of up to 30 g or more of bupropion have been
- reported. Seizure was reported in approximately one third of all cases. Other serious reactions
- reported with overdoses of bupropion alone included hallucinations, loss of consciousness, sinus
- tachycardia, and ECG changes such as conduction disturbances or arrhythmias. Fever, muscle
- rigidity, rhabdomyolysis, hypotension, stupor, coma, and respiratory failure have been reported
- mainly when bupropion was part of multiple drug overdoses.
- Although most patients recovered without sequelae, deaths associated with overdoses of
- bupropion alone have been reported in patients ingesting large doses of the drug. Multiple
- uncontrolled seizures, bradycardia, cardiac failure, and cardiac arrest prior to death were reportedin these patients.
- 770 **Overdosage Management:** Ensure an adequate airway, oxygenation, and ventilation.
- 771 Monitor cardiac rhythm and vital signs. EEG monitoring is also recommended for the first
- 48 hours post-ingestion. General supportive and symptomatic measures are also recommended.
- 773 Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with
- appropriate airway protection, if needed, may be indicated if performed soon after ingestion or insymptomatic patients.
- Activated charcoal should be administered. There is no experience with the use of forced
 diuresis, dialysis, hemoperfusion, or exchange transfusion in the management of bupropion
 overdoses. No specific antidotes for bupropion are known.

- Due to the dose-related risk of seizures with WELLBUTRIN SR, hospitalization following
- suspected overdose should be considered. Based on studies in animals, it is recommended that
- seizures be treated with intravenous benzodiazepine administration and other supportive
- measures, as appropriate.
- In managing overdosage, consider the possibility of multiple drug involvement. The physician
- should consider contacting a poison control center for additional information on the treatment of
- any overdose. Telephone numbers for certified poison control centers are listed in the
- 786 *Physicians' Desk Reference* (PDR).

787 DOSAGE AND ADMINISTRATION

- 788 **General Dosing Considerations:** It is particularly important to administer
- 789 WELLBUTRIN SR Tablets in a manner most likely to minimize the risk of seizure (see
- 790 WARNINGS). Gradual escalation in dosage is also important if agitation, motor restlessness,
- and insomnia, often seen during the initial days of treatment, are to be minimized. If necessary,
- these effects may be managed by temporary reduction of dose or the short-term administration of
- an intermediate to long-acting sedative hypnotic. A sedative hypnotic usually is not required
- beyond the first week of treatment. Insomnia may also be minimized by avoiding bedtime doses.
- 795 If distressing, untoward effects supervene, dose escalation should be stopped.
- 796 WELLBUTRIN SR should be swallowed whole and not crushed, divided, or chewed.
- 797 Initial Treatment: The usual adult target dose for WELLBUTRIN SR Tablets is 300 mg/day,
- given as 150 mg twice daily. Dosing with WELLBUTRIN SR Tablets should begin at
- 150 mg/day given as a single daily dose in the morning. If the 150-mg initial dose is adequately
- tolerated, an increase to the 300-mg/day target dose, given as 150 mg twice daily, may be made
- 801 as early as day 4 of dosing. There should be an interval of at least 8 hours between successive
- 802 doses.
- 803 Increasing the Dosage Above 300 mg/day: As with other antidepressants, the full
- antidepressant effect of WELLBUTRIN SR Tablets may not be evident until 4 weeks of
- treatment or longer. An increase in dosage to the maximum of 400 mg/day, given as 200 mg
- 806 twice daily, may be considered for patients in whom no clinical improvement is noted after
- 807 several weeks of treatment at 300 mg/day.
- 808 Maintenance Treatment: It is generally agreed that acute episodes of depression require
- several months or longer of sustained pharmacological therapy beyond response to the acute
- 810 episode. In a study in which patients with major depressive disorder, recurrent type, who had
- 811 responded during 8 weeks of acute treatment with WELLBUTRIN SR were assigned randomly
- to placebo or to the same dose of WELLBUTRIN SR (150 mg twice daily) during 44 weeks of
- 813 maintenance treatment as they had received during the acute stabilization phase, longer-term
- 814 efficacy was demonstrated (see CLINICAL TRIALS under CLINICAL PHARMACOLOGY).
- 815 Based on these limited data, it is unknown whether or not the dose of WELLBUTRIN SR needed 816 for maintenance treatment is identical to the dose needed to achieve an initial response. Patients

- should be periodically reassessed to determine the need for maintenance treatment and the
- 818 appropriate dose for such treatment.
- 819 **Dosage Adjustment for Patients with Impaired Hepatic Function:** WELLBUTRIN SR
- should be used with extreme caution in patients with severe hepatic cirrhosis. The dose should
- 821 not exceed 100 mg every day or 150 mg every other day in these patients. WELLBUTRIN SR
- should be used with caution in patients with hepatic impairment (including mild to moderate
- hepatic cirrhosis) and a reduced frequency and/or dose should be considered in patients with
- mild to moderate hepatic cirrhosis (see CLINICAL PHARMACOLOGY, WARNINGS, and
- 825 PRECAUTIONS).
- 826 **Dosage Adjustment for Patients with Impaired Renal Function:** WELLBUTRIN SR
- should be used with caution in patients with renal impairment and a reduced frequency and/or
- 828 dose should be considered (see CLINICAL PHARMACOLOGY and PRECAUTIONS).

829 HOW SUPPLIED

- 830 WELLBUTRIN SR Sustained-Release Tablets, 100 mg of bupropion hydrochloride, are blue,
- round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 100" in bottles of 60
 (NDC 0173-0947-55) tablets.
- WELLBUTRIN SR Sustained-Release Tablets, 150 mg of bupropion hydrochloride, are
 purple, round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 150" in bottles of
 60 (NDC 0173-0135-55) tablets.
- WELLBUTRIN SR Sustained-Release Tablets, 200 mg of bupropion hydrochloride, are light
 pink, round, biconvex, film-coated tablets printed with "WELLBUTRIN SR 200" in bottles of 60
 (NDC 0173-0722-00) tablets.
- 839 Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Dispense in a 840 tight, light-resistant container as defined in the USP.
- 841

842	Medication Guide
843	WELLBUTRIN SR [®] (WELL byu-trin)
844	(bupropion hydrochloride) Sustained-Release Tablets
845	About Using Antidepressants in Children and Teenagers
846	
847	What is the most important information I should know if my child is being prescribed an
848	antidepressant?
849	
850	Parents or guardians need to think about 4 important things when their child is prescribed an
851	antidepressant:
852	1. There is a risk of suicidal thoughts or actions
853	2. How to try to prevent suicidal thoughts or actions in your child
854	3. You should watch for certain signs if your child is taking an antidepressant

4. There are benefits and risks when using antidepressants

856

857 1. There is a Risk of Suicidal Thoughts or Actions

858 859

Children and teenager sometimes think about suicide, and many report trying to kill themselves. 860

861 Antidepressants increase suicidal thoughts and actions in some children and teenagers. But

862 suicidal thoughts and actions can also be caused by depression, a serious medical condition that

863 is commonly treated with antidepressants. Thinking about killing yourself or trying to kill

864 yourself is called *suicidality* or *being suicidal*.

865

866 A large study combined the results of 24 different studies of children and teenagers with

867 depression or other illnesses. In these studies, patients took either a placebo (sugar pill) or an

868 antidepressant for 1 to 4 months. No one committed suicide in these studies, but some patients

869 became suicidal. On sugar pills, 2 out of every 100 became suicidal. On the antidepressants, 4

- 870 out of every 100 patients became suicidal.
- 871

874

875

876

872 For some children and teenagers, the risks of suicidal actions may be especially high. These 873 include patients with

- Bipolar illness (sometimes called manic-depressive illness)
- A family history of bipolar illness
 - A personal or family history of attempting suicide

877 If any of these are present, make sure you tell your healthcare provider before your child takes an 878 antidepressant.

879

880 2. How to Try to Prevent Suicidal Thoughts and Actions

881

882 To try to prevent suicidal thoughts and actions in your child, pay close attention to changes in her 883 or his moods or actions, especially if the changes occur suddenly. Other important people in your 884 child's life can help by paying attention as well (e.g., your child, brothers and sisters, teachers, 885 and other important people). The changes to look out for are listed in Section 3, on what to watch 886 for.

887

888 Whenever an antidepressant is started or its dose is changed, pay close attention to your child. 889 After starting an antidepressant, your child should generally see his or her healthcare provider:

- 890 • Once a week for the first 4 weeks
- 891 • Every 2 weeks for the next 4 weeks
- 892 • After taking the antidepressant for 12 weeks
- 893 • After 12 weeks, follow your healthcare provider's advice about how often to come back
- 894 More often if problems or questions arise (see Section 3) •
- 895

896 897	You should call your child's healthcare provider between visits if needed.
898	3. You Should Watch For Certain Signs if Your Child is Taking an Antidepressant
899	5. Tou Should Watch For Certain Signs in Tour Clinic is Taking an Antidepressant
900	Contact your child's healthcare provider <i>right away</i> if your child exhibits any of the following
901	signs for the first time, or they seem worse, or worry you, your child, or your child's teacher:
902	• Thoughts about suicide or dying
903	Attempts to commit suicide
904	New or worse depression
905	• New or worse anxiety
906	• Feeling very agitated or restless
907	• Panic attacks
908	• Difficulty sleeping (insomnia)
909	New or worse irritability
910	Acting aggressive, being angry, or violent
911	Acting on dangerous impulses
912	An extreme increase in activity and talking
913	Other unusual changes in behavior or mood
914	
915	Never let your child stop taking an antidepressant without first talking to his or her healthcare
916	provider. Stopping an antidepressant suddenly can cause other symptoms.
917	
918	4. There are Benefits and Risks When Using Antidepressants
919	
920	Antidepressants are used to treat depression and other illnesses. Depression and other illnesses
921	can lead to suicide. In some children and teenagers, treatment with an antidepressant increases
922 923	suicidal thinking or actions. It is important to discuss all the risks of treating depression and also the risks of not treating it. You and your child should discuss all treatment choices with your
923 924	healthcare provider, not just the use of antidepressants.
924 925	nearmeare provider, not just the use of antidepressants.
925 926	Other side effects can occur with antidepressants (see section below).
927	other side effects can occur with antidepressants (see section below).
928	Of all antidepressants, only fluoxetine (Prozac [®])* has been FDA approved to treat pediatric
929	depression.
930	
931	For obsessive compulsive disorder in children and teenagers, FDA has approved only fluoxetine
932	(Prozac®)*, sertraline (Zoloft [®])*, fluvoxamine, and clomipramine (Anafranil [®])*.
933	
934	Your healthcare provider may suggest other antidepressants based on the past experience of your
935	child or other family members.

	Patient Information WELLBUTRIN SR [®] (WELL byu-trin) (bupropion hydrochloride) Sustained-Release Tablets	
	MACISTDETACH HERE AND GIVE LEAFLET TO PATIENT. ALSO PROVIDE AN APPROVED MEDICATION GUIDE ABOUT USING ANTIDEPRESSANTS IN CHILDREN AND TEENAGERS.	
May 2006	RL-2280	
©2006, Glaz	xoSmithKline. All rights reserved.	
,		
Greenville,		
	naceuticals, Inc.	
or		
	iangle Park, NC 27709	
GlaxoSmith	•	
Manufacture	ad hy:	
GlaxoSmith	Kline, Research Triangle Park, NC 27709	
Distributed	-	
-	xoSmithKline	
5		
January 200	5 MG-MS:1	
annaepressa		
antidepressa		
This Modia	ation Guide has been approved by the U.S. Food and Drug Administration for a	
*The following are registered trademarks of their respective manufacturers: Prozac [®] /Eli Lilly and Company; Zoloft [®] /Pfizer Pharmaceuticals; Anafranil [®] /Mallinckrodt Inc.		
annuepressa	int. Ask your nearlicate provider of pharmacist where to find more information	
-	ug he or she is prescribing. Also ask about drugs to avoid when taking an nt. Ask your healthcare provider or pharmacist where to find more information.	
-	ints. Be sure to ask your healthcare provider to explain all the side effects of the	
	a warning about the risk of suicidality. Other side effects can occur with	
Is this all I	need to know if my child is being prescribed an antidepressant?	

 Read the Patient Information that comes with WELLBUTRIN SR before you start taking WELLBUTRIN SR and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment. What is the most important information I should know about WELLBUTRIN SR? There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially in people: with certain medical problems. who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. Hyou have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenager." What is WELLBUTRIN SR? What is important information and indicpressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with accertain type of depression called major depressive disorder. What is important information I should know and share with my family about taking antidepressants? What is important information	971	
 does not take the place of talking with your doctor about your medical condition or your treatment. What is the most important information I should know about WELLBUTRIN SR? There is a chance of having a scizure (convulsion, fit) with WELLBUTRIN SR, especially in people: with certain medical problems. who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feeling such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. What is WELLBUTRIN SR? Wor should not take WELLBUTRIN SR? Do not take WELLBUT	972	Read the Patient Information that comes with WELLBUTRIN SR before you start taking
 treatment. What is the most important information I should know about WELLBUTRIN SR? There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially in people: with certain medical problems. who take certain medicines. The chance of having scizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a scizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperaetive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. What is WELLBUTRIN SR? (used to help people stop smoking) or any other medicines that	973	WELLBUTRIN SR and each time you get a refill. There may be new information. This leaflet
 976 977 What is the most important information I should know about WELLBUTRIN SR? 978 There is a chance of having a scizure (convulsion, fit) with WELLBUTRIN SR, especially 979 in people: 970 • with certain medical problems. 981 • who take certain medicines. 982 The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more 983 information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I 984 tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical 985 conditions and all the medicines you take. Do not take any other medicines while you are 986 using WELLBUTRIN SR unless your doctor has said it is okay to take them. 987 9 988 9 989 9 990 Hyperactive while taking WELLBUTRIN SR, stop taking the tablets and call your 991 doctor right away. Do not take WELLBUTRIN SR again if you have a scizure. 992 9 994 9 994 Patients and their families should watch out for worsening depression or thoughts of suicide. 995 Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, 996 panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and 997 hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, 998 especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. 994 WELLBUTRIN SR entited "About Using Antidepressants in Children and Teenagers." 995 WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of 996 depression called major depressive disorder. 900 901 WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of 902 depression called major depressive disorder. 903 0 hot take WELLBUTRIN SR?	974	does not take the place of talking with your doctor about your medical condition or your
 What is the most important information I should know about WELLBUTRIN SR? There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially in people: with certain medical problems. who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressants treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR? What is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. What is wellbutRIN SR is a prescription medicine used to treat adults with a certain type of depression called major	975	treatment.
 There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially in people: with certain medical problems. who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR? What is WELLBUTRIN SR? Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 	976	
 There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially in people: with certain medical problems. who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that	977	What is the most important information I should know about WELLBUTRIN SR?
 with certain medical problems. who take certain medicines. who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR? No should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you<td>978</td><td>There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially</td>	978	There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN SR, especially
 who take certain medicines. The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 	979	in people:
 The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers." WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Whos should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 	980	• with certain medical problems.
 The chance of having seizures increases with higher doses of WELLBUTRIN SR. For more information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for suden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR? What is WELLBUTRIN SR? What is WELLBUTRIN SR? Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 	981	• who take certain medicines.
 information, see the sections "Who should not take WELLBUTRIN SR?" and "What should I tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR? What is WELLBUTRIN SR? Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR? Do not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 	982	
 tell my doctor before using WELLBUTRIN SR?" Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR? What is WELLBUTRIN SR? What is WELLBUTRIN SR? Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		6 6
 conditions and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers." What is WELLBUTRIN SR? What is WELLBUTRIN SR? What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 using WELLBUTRIN SR unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 If you have a seizure while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		using welled of Kitt SK unless your doctor has sald it is okay to take them.
 doctor right away. Do not take WELLBUTRIN SR again if you have a seizure. What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? What is WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		If you have a solution while taking WELL BUTDIN SD stop taking the tablets and call your
 991 992 What is important information I should know and share with my family about taking 993 antidepressants? 994 Patients and their families should watch out for worsening depression or thoughts of suicide. 995 Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, 996 panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and 997 hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, 998 especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. 999 A patient Medication Guide will be provided to you with each prescription of 900 WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." 1001 WELLBUTRIN SR is not approved for use in children and teenagers. 1002 1003 What is WELLBUTRIN SR? 1004 WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of 1005 depression called major depressive disorder. 1006 1007 Who should not take WELLBUTRIN SR? 108 Do not take WELLBUTRIN SR if you 1099 have or had a seizure disorder or epilepsy. 1000 are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 What is important information I should know and share with my family about taking antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		uoctor right away. Do not take wellebo rkin SK again ir you have a seizure.
 antidepressants? Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		What is important information I should know and share with my family about taking
 Patients and their families should watch out for worsening depression or thoughts of suicide. Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. WeELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		•
 Also watch out for sudden or severe changes in feelings such as feeling anxious, agitated, panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		-
 panicky, irritable, hostile, aggressive, impulsive, severely restless, overly excited and hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? WellBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 997 hyperactive, not being able to sleep, or other unusual changes in behavior. If this happens, 998 especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. 999 A patient Medication Guide will be provided to you with each prescription of 1000 WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." 1001 WELLBUTRIN SR is not approved for use in children and teenagers. 1002 1003 What is WELLBUTRIN SR? 1004 WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of 1005 depression called major depressive disorder. 1006 1007 Who should not take WELLBUTRIN SR? 1008 Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. 1010 are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 especially at the beginning of antidepressant treatment or after a change in dose, call your doctor. A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. Wettaut is WellBUTRIN SR? Wettaut is wellBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WellBUTRIN SR? Do not take WellBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 A patient Medication Guide will be provided to you with each prescription of WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 WELLBUTRIN SR entitled "About Using Antidepressants in Children and Teenagers." WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 WELLBUTRIN SR is not approved for use in children and teenagers. What is WELLBUTRIN SR? WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		I I J I I
 1002 1003 What is WELLBUTRIN SR? 1004 WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of 1005 depression called major depressive disorder. 1006 1007 Who should not take WELLBUTRIN SR? 1008 Do not take WELLBUTRIN SR if you 1009 have or had a seizure disorder or epilepsy. 1010 are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 What is WELLBUTRIN SR? WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 WELLBUTRIN SR is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		What is WELLBUTRIN SR?
 depression called major depressive disorder. Who should not take WELLBUTRIN SR? Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 1006 1007 Who should not take WELLBUTRIN SR? 1008 Do not take WELLBUTRIN SR if you 1009 have or had a seizure disorder or epilepsy. 1010 are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 1007 Who should not take WELLBUTRIN SR? 1008 Do not take WELLBUTRIN SR if you 1009 have or had a seizure disorder or epilepsy. 1010 are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
 Do not take WELLBUTRIN SR if you have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		Who should not take WELLBUTRIN SR?
 have or had a seizure disorder or epilepsy. are taking ZYBAN[®] (used to help people stop smoking) or any other medicines that 		
• are taking ZYBAN [®] (used to help people stop smoking) or any other medicines that		•
contain suproprion nyarochioritae, such as the medication in the medication of the m	1011	contain bupropion hydrochloride, such as WELLBUTRIN [®] Tablets or WELLBUTRIN

1012	XL [®] Extended-Release Tablets. Bupropion is the same active ingredient that is in
1013	WELLBUTRIN SR.
1014	• drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these
1015	make you sleepy) or benzodiazepines and you stop using them all of a sudden.
1016	• have taken within the last 14 days medicine for depression called a monoamine oxidase
1017	inhibitor (MAOI), such as $\text{NARDIL}^{\mathbb{R}^*}$ (phenelzine sulfate), $\text{PARNATE}^{\mathbb{R}}$ (tranylcypromine
1018	sulfate), or MARPLAN ^{®*} (isocarboxazid).
1019	 have or had an eating disorder such as anorexia nervosa or bulimia.
1020	• are allergic to the active ingredient in WELLBUTRIN SR, bupropion, or to any of the
1021	inactive ingredients. See the end of this leaflet for a complete list of ingredients in
1022	WELLBUTRIN SR.
1023	
1024	What should I tell my doctor before using WELLBUTRIN SR?
1025	• Tell your doctor about your medical conditions. Tell your doctor if you:
1026	• are pregnant or plan to become pregnant. It is not known if WELLBUTRIN SR can
1027	harm your unborn baby. If you can use WELLBUTRIN SR while you are pregnant, talk
1028	to your doctor about how you can be on the Bupropion Pregnancy Registry.
1029	• are breastfeeding. WELLBUTRIN SR passes through your milk. It is not known if
1030	WELLBUTRIN SR can harm your baby.
1031	• have liver problems, especially cirrhosis of the liver.
1032	 have kidney problems.
1033	 have an eating disorder such as anorexia nervosa or bulimia.
1034	 have had a head injury.
1035	• have had a seizure (convulsion, fit).
1036	 have a tumor in your nervous system (brain or spine).
1037	 have had a heart attack, heart problems, or high blood pressure.
1038	• are a diabetic taking insulin or other medicines to control your blood sugar.
1039	• drink a lot of alcohol.
1040	 abuse prescription medicines or street drugs.
1041	
1042	• Tell your doctor about all the medicines you take, including prescription and non-
1043	prescription medicines, vitamins, and herbal supplements. Many medicines increase your
1044	chances of having seizures or other serious side effects if you take them while you are using
1045	WELLBUTRIN SR.
1046	
1047	WELLBUTRIN SR has not been studied in children under the age of 18 years.
1048	
1049	How should I take WELLBUTRIN SR?
1050	• Take WELLBUTRIN SR exactly as prescribed by your doctor.

1051	• Do not chew, cut, or crush WELLBUTRIN SR Tablets. You must swallow the tablets	
1052	whole. Tell your doctor if you cannot swallow medicine tablets.	
1053	• Take WELLBUTRIN SR at the same time each day.	
1054	• Take your doses of WELLBUTRIN SR at least 8 hours apart.	
1055	• You may take WELLBUTRIN SR with or without food.	
1056	• If you miss a dose, do not take an extra tablet to make up for the dose you forgot. Wait and	
1057	take your next tablet at the regular time. This is very important. Too much	
1058	WELLBUTRIN SR can increase your chance of having a seizure.	
1059	• If you take too much WELLBUTRIN SR, or overdose, call your local emergency room or	
1060	poison control center right away.	
1061	• Do not take any other medicines while using WELLBUTRIN SR unless your doctor ha	S
1062	told you it is okay.	
1063	• It may take several weeks for you to feel that WELLBUTRIN SR is working. Once you feel	
1064	better, it is important to keep taking WELLBUTRIN SR exactly as directed by your doctor.	
1065	Call your doctor if you do not feel WELLBUTRIN SR is working for you.	
1066	• Do not change your dose or stop taking WELLBUTRIN SR without talking with your docto	r
1067	first.	
1068		
1069	What should I avoid while taking WELLBUTRIN SR?	
1070	• Do not drink a lot of alcohol while taking WELLBUTRIN SR. If you usually drink a lot of	
1071	alcohol, talk with your doctor before suddenly stopping. If you suddenly stop drinking	
1072	alcohol, you may increase your chance of having seizures.	
1073	• Do not drive a car or use heavy machinery until you know how WELLBUTRIN SR affects	
1074	you. WELLBUTRIN SR can impair your ability to perform these tasks.	
1075		
1076	What are possible side effects of WELLBUTRIN SR?	
1077	• Seizures. Some patients get seizures while taking WELLBUTRIN SR. If you have a seizur	e
1078	while taking WELLBUTRIN SR, stop taking the tablets and call your doctor right	
1079	away. Do not take WELLBUTRIN SR again if you have a seizure.	
1080	• Hypertension (high blood pressure). Some patients get high blood pressure, sometimes	
1081	severe, while taking WELLBUTRIN SR. The chance of high blood pressure may be	
1082	increased if you also use nicotine replacement therapy (for example, a nicotine patch) to help	р
1083	you stop smoking.	
1084	• Severe allergic reactions: Stop taking WELLBUTRIN SR and call your doctor right	
1085	away if you get a rash, itching, hives, fever, swollen lymph glands, painful sores in the	
1086	mouth or around the eyes, swelling of the lips or tongue, chest pain, or have trouble	
1087	breathing. These could be signs of a serious allergic reaction.	
1088	• Unusual thoughts or behaviors. Some patients have unusual thoughts or behaviors while	
1089	taking WELLBUTRIN SR, including delusions (believe you are someone else),	

- 1090 hallucinations (seeing or hearing things that are not there), paranoia (feeling that people are 1091 against you), or feeling confused. If this happens to you, call your doctor. 1092 1093 The most common side effects of WELLBUTRIN SR are loss of appetite, dry mouth, skin rash, 1094 sweating, ringing in the ears, shakiness, stomach pain, agitation, anxiety, dizziness, trouble sleeping, muscle pain, nausea, fast heart beat, sore throat, and urinating more often. 1095 1096 1097 If you have nausea, you may want to take your medicine with food. If you have trouble sleeping, 1098 do not take your medicine too close to bedtime. 1099 1100 Tell your doctor right away about any side effects that bother you. 1101 1102 These are not all the side effects of WELLBUTRIN SR. For a complete list, ask your doctor or 1103 pharmacist. 1104 1105 How should I store WELLBUTRIN SR? 1106 Store WELLBUTRIN SR at room temperature. Store out of direct sunlight. Keep 1107 WELLBUTRIN SR in its tightly closed bottle. 1108 • WELLBUTRIN SR tablets may have an odor. 1109 1110 **General Information about WELLBUTRIN SR.** 1111 • Medicines are sometimes prescribed for conditions that are not mentioned in patient 1112 information leaflets. Do not use WELLBUTRIN SR for a condition for which it was not prescribed. Do not give WELLBUTRIN SR to other people, even if they have the same 1113 1114 symptoms you have. It may harm them. Keep WELLBUTRIN SR out of the reach of 1115 children 1116 1117 This leaflet summarizes important information about WELLBUTRIN SR. For more information, 1118 talk with your doctor. You can ask your doctor or pharmacist for information about 1119 WELLBUTRIN SR that is written for health professionals. 1120 1121 What are the ingredients in WELLBUTRIN SR? 1122 Active ingredient: bupropion hydrochloride. 1123 1124 Inactive ingredients: carnauba wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide. In 1125 addition, the 100-mg tablet contains FD&C Blue No. 1 Lake, the 150-mg tablet contains FD&C 1126 1127 Blue No. 2 Lake and FD&C Red No. 40 Lake, and the 200-mg tablet contains FD&C Red No. 40 1128 Lake. The tablets are printed with edible black ink. 1129
 - 31

- 1130 *The following are registered trademarks of their respective manufacturers: Nardil[®]/Warner
- 1131 Lambert Company; Marplan[®]/Oxford Pharmaceutical Services, Inc.
- 1132
- 1133 R_xonly
- 1134

gsk GlaxoSmithKline

- 1135 1136 Distributed by:
- 1137 GlaxoSmithKline
- 1138 Research Triangle Park, NC 27709
- 1139
- 1140 Manufactured by:
- 1141 GlaxoSmithKline
- 1142 Research Triangle Park, NC 27709
- 1143 or
- 1144 DSM Pharmaceuticals, Inc.
- 1145 Greenville, NC 27834
- 1146
- 1147 ©2006, GlaxoSmithKline. All rights reserved.
- 1148
- 1149 May 2006 RL-2280